CGEN

Compugen (CGEN)

Compugen Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CGEN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/17	20 : 00	PR Newswire (US)	Compugen to Present at Upcoming Antibody Industrial Symposium	NASDAQ:CGEN	Compugen Ltd
2024/05/30	20 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/05/30	20 : 00	PR Newswire (US)	Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	NASDAQ:CGEN	Compugen Ltd
2024/05/20	20 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/05/20	20 : 00	PR Newswire (US)	Compugen Reports First Quarter 2024 Results	NASDAQ:CGEN	Compugen Ltd
2024/05/20	19 : 59	IH Market News	U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip	NASDAQ:CGEN	Compugen Ltd
2024/05/16	20 : 00	PR Newswire (US)	Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential	NASDAQ:CGEN	Compugen Ltd
2024/05/15	20 : 02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/05/15	20 : 00	PR Newswire (US)	Compugen Appoints David Silberman as Chief Financial Officer	NASDAQ:CGEN	Compugen Ltd
2024/05/06	20 : 00	PR Newswire (US)	Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024	NASDAQ:CGEN	Compugen Ltd
2024/04/25	20 : 00	PR Newswire (US)	Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	NASDAQ:CGEN	Compugen Ltd
2024/04/10	20 : 00	PR Newswire (US)	Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503	NASDAQ:CGEN	Compugen Ltd
2024/04/03	20 : 00	PR Newswire (US)	Compugen to Participate in Two Upcoming Investor Conferences	NASDAQ:CGEN	Compugen Ltd
2024/03/11	20 : 00	PR Newswire (US)	Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	NASDAQ:CGEN	Compugen Ltd
2024/03/06	21 : 00	PR Newswire (US)	Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	NASDAQ:CGEN	Compugen Ltd
2024/03/06	06 : 06	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:CGEN	Compugen Ltd
2024/03/05	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/03/05	21 : 00	PR Newswire (US)	Compugen Reports Fourth Quarter and Full Year 2023 Results	NASDAQ:CGEN	Compugen Ltd
2024/03/05	20 : 05	IH Market News	U.S. Futures Dip, Crude Oil Fluctuates	NASDAQ:CGEN	Compugen Ltd
2024/02/26	21 : 00	PR Newswire (US)	Compugen to Present at the Leerink Partners Global Biopharma Conference 2024	NASDAQ:CGEN	Compugen Ltd
2024/02/20	21 : 00	PR Newswire (US)	Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024	NASDAQ:CGEN	Compugen Ltd
2024/02/15	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/02/15	21 : 00	PR Newswire (US)	Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer	NASDAQ:CGEN	Compugen Ltd
2024/01/08	21 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/01/08	21 : 05	PR Newswire (US)	Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer	NASDAQ:CGEN	Compugen Ltd
2024/01/08	21 : 00	PR Newswire (US)	Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:CGEN	Compugen Ltd
2023/12/19	23 : 30	AllPennyStocks.com	Strong Open For Biotech Following Exclusive Agreement Announcement	NASDAQ:CGEN	Compugen Ltd
2023/12/19	21 : 12	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2023/12/19	21 : 10	PR Newswire (US)	Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer	NASDAQ:CGEN	Compugen Ltd
2023/12/19	21 : 05	PR Newswire (US)	Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology	NASDAQ:CGEN	Compugen Ltd